We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis has agreed to manufacture Carisma Therapeutics’ new line of bioengineered macrophages which, like CAR-T cells, can be reprogrammed to attack patient-specific tumors. Read More
Accused of stealing trade secrets through a former employee of AbbVie’s, Alvotech will pay royalties to AbbVie for licensing its patents in July 2023. Read More
A newly proposed bill would make it easier for the FDA to expeditiously remove drugs marketed on accelerated approvals if they don’t live up to their clinical promise. Read More
Antibody developer Adagene has forged a collaboration and exclusive license agreement with Sanofi to make masked monoclonal and bispecific antibodies. Read More